News Agency
Men's Weekly

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

  • Written by PR Newswire
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious...

Read more: Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2...

Managing Business Risk Through Content Governance in Headless CMS

As businesses scale their digital presence, content becomes a critical asset that directly impacts reputation, compliance, and operational efficiency. However, without proper governance, content can quickly become a source of risk. Inaccurate information, inconsistent messaging, or non-compliant content can lead... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion